Li Chu
Impact in
- Pharmacology top 2%
- Drug-Induced Hepatotoxicity and Protection
-
- Traditional Chinese Medicine Analysis
Papers in
-
- Chemotherapy-induced cardiotoxicity and mitigation 9
- Cardiac Fibrosis and Remodeling 8
- Cardiac electrophysiology and arrhythmias 5
-
- Cardiac Ischemia and Reperfusion 13
- Co-authors
- Jianping Zhang (42 shared papers)Xi Chu (33 shared papers)Xue Han (25 shared papers)Xuan Zhang (22 shared papers)Zhihong Ma (13 shared papers)Yucong Xue (16 shared papers)Xue Han (14 shared papers)Bin Zheng (16 shared papers)
- Journals
- Biomedicine & Pharmacotherapy (10 papers)Radiation Oncology (6 papers)Frontiers in Pharmacology (6 papers)International Immunopharmacology (6 papers)PLoS ONE (5 papers)
- Partner nations
- ChinaJapanUnited States
In The Last Decade
Li Chu
179 papers receiving 3.9k citations
Peers
Comparison fields: 5 of 88
- Pharmacology 182
- Complementary and alternative medicine 156
- Cardiology and Cardiovascular Medicine 332
- Drug Discovery 1
- Oncology 232
Countries citing papers authored by Li Chu
This map shows the geographic impact of Li Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Chu more than expected).
Fields of papers citing papers by Li Chu
This network shows the impact of papers produced by Li Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Chu. The network helps show where Li Chu may publish in the future.
Co-authors
The 25 scholars most cited alongside Li Chu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 183 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 97 | |
| 2 | 2017 | 90 | |
| 3 | 2021 | 87 | |
| 4 | 2022 | 84 | |
| 5 | 2018 | 80 | |
| 6 | 2017 | 74 | |
| 7 | 2020 | 68 | |
| 8 | 2020 | 65 | |
| 9 | 2017 | 61 | |
| 10 | 2021 | 60 | |
| 11 | 2017 | 58 | |
| 12 | 2021 | 58 | |
| 13 | 2019 | 56 | |
| 14 | 2013 | 52 | |
| 15 | 2014 | 52 | |
| 16 | 2016 | 49 | |
| 17 | 2018 | 48 | |
| 18 | 2020 | 48 | |
| 19 | 2016 | 47 | |
| 20 | 2019 | 47 |
About Li Chu
Li Chu is a scholar working on Cardiology and Cardiovascular Medicine, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Oncology and Pharmacology, having authored 183 papers that have together received 3.9k indexed citations. Recurring topics across this work include Cardiac Ischemia and Reperfusion (13 papers), Lung Cancer Treatments and Mutations (12 papers), Esophageal Cancer Research and Treatment (12 papers), Nitric Oxide and Endothelin Effects (10 papers), Chemotherapy-induced cardiotoxicity and mitigation (9 papers), Cardiac Fibrosis and Remodeling (8 papers), Brain Metastases and Treatment (5 papers) and Cardiac electrophysiology and arrhythmias (5 papers). The work is most often cited by research in Pharmacology (182 citations), Complementary and alternative medicine (156 citations), Cardiology and Cardiovascular Medicine (332 citations), Drug Discovery (1 citation) and Oncology (232 citations). Li Chu has collaborated with scholars based in China, Japan and United States. Frequent co-authors include Jianping Zhang, Xi Chu, Xue Han, Xuan Zhang, Zhihong Ma, Yucong Xue, Xue Han, Bin Zheng, Shengjiang Guan and Xi Yang. Their work appears in journals such as Biomedicine & Pharmacotherapy, Radiation Oncology, Frontiers in Pharmacology, International Immunopharmacology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.